Liquid Biopsy Testing Can Improve Selection of Advanced Non-Small-Cell Lung Cancer Patients to Rechallenge with Gefitinib

Liquid Biopsy Testing Can Improve Selection of Advanced Non-Small-Cell Lung Cancer Patients to Rechallenge with Gefitinib

The ICARUS trial is a phase II, open label, multicenter, single arm study conducted to investigate the efficacy, safety, and tolerability of a rechallenge treatment with the first-generation tyrosine kinase inhibitor (TKI) gefitinib in advanced non-small-cell lung cancer (NSCLC) patients carrying ac...

Full description

Bibliographic Details
Main Authors: Riziero Esposito Abate, Raffaella Pasquale, Alessandra Sacco, Maria Carmela Piccirillo, Alessandro Morabito, Paolo Bidoli, Giovanna Finocchiaro, Rita Chiari, Luisa Foltran, Roberta Buosi, Marcello Tiseo, Laura Giannetta, Ciro Battiloro, Gianpiero Fasola, Gianpiero Romano, Libero Ciuffreda, Antonio Frassoldati, Filippo de Marinis, Federico Cappuzzo, Nicola Normanno
Format: Article
Language:English
Published: MDPI AG 2019-09-01
Series:Cancers
Subjects:
non-small-cell lung cancer
rechallenge
resistance
liquid biopsy
p.t790m
Online Access:https://www.mdpi.com/2072-6694/11/10/1431

Internet

https://www.mdpi.com/2072-6694/11/10/1431

Similar Items